$28.10
Today
as of Jul 22, 16:55 ET
Last 30 days
Recent Press Releases & News
Mizuho Raises Price Target on Tango Therapeutics to $40 From $36, Keeps Outperform Rating
Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
Overview
52-week range
$3.12
$28
99% of range
Avg surprise (last 3)
-2.0%
Avg reaction (last 2)
+11.7%
100% positive
Latest IV / EM
83%
EM ±19.0% · $28 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 13, 2026 | Mar/2026 | $-0.32 | $-0.32 | 0.0% | +11.1% | +8.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.13 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-0.35 | $-0.35 | 0.0% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.36 | $-0.34 | -5.9% | — | +14.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.27 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.24 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.35 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.23 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.23 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | OTHER | -$0.31 | -$0.35 | +11.4% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | — | $54M | $3M | $5M | — | $12M | $20M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-49M | — | $14M | $-41M | $-43M | — | $-33M | $-30M |
| Net income | $-46M | — | $16M | $-39M | $-40M | — | $-29M | $-26M |
| EPS (diluted) | $-0.32 | — | $0.13 | $-0.35 | $-0.36 | — | $-0.27 | $-0.24 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $158M | $112M | $58M | $39M | $58M | $70M | $53M | $52M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $392M | $354M | $164M | $190M | $225M | $266M | $301M | $328M |
| Total assets | $436M | $399M | $210M | $238M | $274M | $316M | $352M | $381M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $44M | $53M | $50M | $103M | $108M | $117M | $123M | $134M |
| Total equity | $392M | $346M | $160M | $135M | $167M | $200M | $229M | $248M |